rs370196002
Positions:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_024915.4(GRHL2):c.1723G>A(p.Val575Met) variant causes a missense change. The variant allele was found at a frequency of 0.0000657 in 1,613,514 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000069 ( 0 hom. )
Consequence
GRHL2
NM_024915.4 missense
NM_024915.4 missense
Scores
7
12
Clinical Significance
Conservation
PhyloP100: 3.62
Genes affected
GRHL2 (HGNC:2799): (grainyhead like transcription factor 2) The protein encoded by this gene is a transcription factor that can act as a homodimer or as a heterodimer with either GRHL1 or GRHL3. Defects in this gene are a cause of non-syndromic sensorineural deafness autosomal dominant type 28 (DFNA28).[provided by RefSeq, Mar 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.17054152).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GRHL2 | NM_024915.4 | c.1723G>A | p.Val575Met | missense_variant | 15/16 | ENST00000646743.1 | NP_079191.2 | |
GRHL2 | NM_001330593.2 | c.1675G>A | p.Val559Met | missense_variant | 15/16 | NP_001317522.1 | ||
GRHL2 | XM_011517306.4 | c.1675G>A | p.Val559Met | missense_variant | 15/16 | XP_011515608.1 | ||
GRHL2 | XM_011517307.4 | c.1723G>A | p.Val575Met | missense_variant | 15/16 | XP_011515609.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GRHL2 | ENST00000646743.1 | c.1723G>A | p.Val575Met | missense_variant | 15/16 | NM_024915.4 | ENSP00000495564 | P1 | ||
GRHL2 | ENST00000395927.1 | c.1675G>A | p.Val559Met | missense_variant | 15/16 | 2 | ENSP00000379260 | |||
GRHL2 | ENST00000474338.1 | n.365G>A | non_coding_transcript_exon_variant | 4/4 | 3 | |||||
GRHL2 | ENST00000517674.5 | n.292G>A | non_coding_transcript_exon_variant | 4/4 | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152104Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
5
AN:
152104
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251342Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135838
GnomAD3 exomes
AF:
AC:
10
AN:
251342
Hom.:
AF XY:
AC XY:
6
AN XY:
135838
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000691 AC: 101AN: 1461410Hom.: 0 Cov.: 30 AF XY: 0.0000756 AC XY: 55AN XY: 727054
GnomAD4 exome
AF:
AC:
101
AN:
1461410
Hom.:
Cov.:
30
AF XY:
AC XY:
55
AN XY:
727054
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152104Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74296
GnomAD4 genome
AF:
AC:
5
AN:
152104
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74296
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
6
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 08, 2013 | Variant classified as Uncertain Significance - Favor Benign. The Val575Met varia nt in GRHL2 has not been reported in the literature nor previously identified by our laboratory. Computational analyses (biochemical amino acid properties, cons ervation, AlignGVGD, PolyPhen2, and SIFT) suggest that the Val575Met variant may not impact the protein, though this information is not predictive enough to rul e out pathogenicity. This variant has been seen in 0.01% (1/8600) of European Am erican chromosomes in a broad population by the NHLBI Exome sequencing project. (http://evs.gs.washington.edu/EVS/), however this frequency is not high enough t o rule out a pathogenic role. In addition, the GRHL2 gene is associated with au tosomal dominant post-lingual hearing loss which is not consistent with this ind ividual?s family history. In summary, the clinical significance of this variant cannot be determined with certainty; however, based upon computational analyses described above and the absence of an autosomal dominant family history, we wou ld lean towards a more likely benign role. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 16, 2022 | The c.1723G>A (p.V575M) alteration is located in exon 15 (coding exon 15) of the GRHL2 gene. This alteration results from a G to A substitution at nucleotide position 1723, causing the valine (V) at amino acid position 575 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 23, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Autosomal dominant nonsyndromic hearing loss 28;C4014987:Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome;C4747961:Corneal dystrophy, posterior polymorphous, 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jul 28, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M;.
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;.;N
REVEL
Benign
Sift
Benign
T;.;T
Sift4G
Benign
T;.;T
Polyphen
P;P;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at